Evidence-Based Medicine Guidelines
Intravenous immunoglobulin for Guillain-Barré syndrome
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Intravenous Immunoglobulin for Guillain-Barré Syndrome." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451719/all/Intravenous_immunoglobulin_for_Guillain_Barré_syndrome.
Intravenous immunoglobulin for Guillain-Barré syndrome. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/451719/all/Intravenous_immunoglobulin_for_Guillain_Barré_syndrome. Accessed March 14, 2025.
Intravenous immunoglobulin for Guillain-Barré syndrome. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/451719/all/Intravenous_immunoglobulin_for_Guillain_Barré_syndrome
Intravenous Immunoglobulin for Guillain-Barré Syndrome [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 14]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451719/all/Intravenous_immunoglobulin_for_Guillain_Barré_syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Intravenous immunoglobulin for Guillain-Barré syndrome
ID - 451719
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451719/all/Intravenous_immunoglobulin_for_Guillain_Barré_syndrome
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
